scarica pdf
Transcript
scarica pdf
Test biochimici: prevedere la preeclampsia Paolo Accorsi Carpi Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 In a normal pregnancy, normal placentation and subsequent spiral artery remodeling occurs, wherein narrow-caliber high-resistance vessels transform into wide-caliber low-resistance vessels owing to the replacement of spiral arterial vascular endothelial cells and vascular smooth muscle resulting from extravillous trophoblasts invading the decidua. This prevents spiral arterial constriction and maintains abundant blood flow, leading to increased oxygen partial pressure in the placental intervillous space 2 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 … balance between antiangiogenic and angiogenic factors should be investigated to elucidate the various pathological features of preeclampsia. Their accurate evaluation is needed to investigate not only antiangiogenic factors (such as sFlt-1 and sEng) and angiogenic factors (such as vascular endothelial growth factor, placental growth factor and transforming growth factor-beta) but also the expression level of their receptors such as Flt-1 and Eng. The levels of syncytiotrophoblast microparticles (STBMs), which have proinflammatory and antiangiogenic activity, are significantly higher in preeclampsia patients… 3 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Preeclampsia is characterized by abnormal implantation/placentation before the abnormal placental bed vascular remodeling, leading to placental hypoxia, secretion of proinflammatory cytokines, and the release of antiangiogenic and angiogenic factors and of syncytiotrophoblast microparticles (STBMs). Both antiangiogenic factors and STBMs have been demonstrated to play an important role in the development of the maternal syndrome of PE. … a poorly perfused placenta, as observed in the first stage, is not sufficient to cause the maternal syndrome …it remains difficult to explain the various pathogenic features of preeclampsia from the viewpoint of antiangiogenic factors and/or STBMs… 4 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 …for elucidating the various physiological features of preeclampsia, it is necessary to accurately evaluate the balance between the plasma levels of antiangiogenic and angiogenic factors and the expression levels of their receptors. Acta Obstet Gynecol Scand 2014; 93: 959–964 5 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 …Because sFlt-1 is a soluble receptor of vascular endothelial growth factor (VEGF), whereas PlGF, a factor belonging to the VEGF family, is a ligand of sFlt-1, the overproduction of sFlt-1 and low levels of PlGF occurring in preeclampsia lead to reduced free VEGF levels, thereby suppressing placental angiogenesis. …Even if sFlt-1 production is not increased, reduced VEGF production may therefore result in the onset of preeclampsia. Moreover, even if VEGF production increases adequately, a larger increase in sFlt-1 levels may lead to the onset of preeclampsia through a decrease in free VEGF. These reports indicate the variable pathological features of preeclampsia and emphasize the importance of accurately examining the balance of antiangiogenic and angiogenic factors, including the expression levels of their receptors Acta Obstet Gynecol Scand 2014; 93: 959–964 6 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04 7 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 The most widely studied serum markers for PE are vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) and their antagonists, namely, soluble fmslike tyrosine kinase 1 (sFlt-1, also known as sVEGFR1), and soluble endoglin (sEng) § sFlt-1 circulates freely in the serum, where it binds and neutralizes VEGF and PlGF. The sFlt-1 levels are correlated directly with severity of disease and they are inversely related with time to onset of proteinuria and hypertension. § sEng is a potential anti-angiogenic factor … which affects production of nitric oxide (NO), vasodilation, and capillary formation by endothelial cells in vitro. It has been reported that sEng is elevated in second-trimester maternal serum in patients who are destined to develop severe preeclampsia… Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04 8 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 § Both VEGF and PlGF, one of the variants of VEGF, are key players in this process. The level of free PlGF in blood is found to be decreased in PE, though normally, its concentration increases during first 30 weeks of gestation. The low concentration of free VEGF in PE is difficult to measure by the commercially available ELISA kits. § Placental protein 13 (PP-13) is a relatively small dimer protein. It probably has an immunobiological function at the foeto-maternal interface and in maternal vascular remodelling. The levels of PP-13 in serum gradually increase in normal pregnancy, but abnormally low levels of PP-13 were detected in first trimester serum samples of women who subsequently developed preeclampsia and IUGR. Combined measuring of maternal serum PP-13 and median uterine artery pulsatility index by using ultrasound early in pregnancy seems to predict severe PE. Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04 9 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 § Pregnancy-associated plasma protein-A (PAPP-A) is a syncytiotrophoblast derived metalloproteinase, which enhances the mitogenic function of the insulin-like growth factors by cleaving the complex formed between such growth factors and their binding proteins. It was reported that decreased plasma levels of PAPP-A seen in first trimester were associated with PE. The insulin-like growth factor system is believed to play an important role in placental growth and development; it is therefore not surprising that low serum PAPP-A is associated with a higher incidence of PE. Increased level of maternal serum PAPP-A has been observed in established PE. Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04 10 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04 11 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 PE & esiti: possibili fattori confondenti • E’ una patologia sola o sono 2 quadri diversi (“early” & “late”)? • Quali esiti si devono considerare? -Parto pretermine? <34w? Lo decidiamo spesso noi e/o i neonatologi… -FGR? Gli studi sono su popolazioni miste, di diverse etnie variamente “mescolate”. PE senza FGR, FGR senza PE… • Incidenza della patologia varia tra etnie (> presenza in afro-caraibiche e sud-asiatiche vs caucasiche). • Per la bassa prevalenza della patologia, almeno quella più rilevante clinicamente, occorrono grandi numeri per avere risultati significativi. 12 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Test biochimici per prevedere la preeclampsia? 13 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Prevedere la preeclampsia? Fetal Diagn Ther 2012;32:171–178 (FMF) Esito: Preeclampsia con parto <34W (FPR 10%), Detection Rate Caratteristiche materne: 50.5% Caratteristiche materne + PI uterine: 75.2% Caratteristiche materne + MAP: 72.9% Caratteristiche materne + MAP + PI u.: 89.7% Nota: selezione della popolazione senza biochimica… 14 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Prevedere la preeclampsia? Fetal Diagn Ther 2013;33:8–15 (FMF) Esito: Preeclampsia con parto <34W (FPR 10%), Detection Rate [1426 donne che hanno sviluppato PE ad ogni epoca di gravidanza] Caratteristiche materne: 50.5% Caratteristiche materne + MAP + PI u.: 89.7% “ + MAP + PI u. + PAPP-A: 92.5% “ + MAP + PI u. + PAPP-A + PlGF: 96.3% Nota: potrebbe identificare la quasi totalità delle PE < 34 W, Quindi dovrebbe/potrebbe essere un buon test di screening 15 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Quale modalità di selezione della popolazione? Fetal Diagn Ther 2013;33:8–15 (FMF) Esito: Preeclampsia con parto <34W 214 su 57458 (0,4%) [1426 donne che hanno sviluppato PE ad ogni epoca di gravidanza] Caratteristiche materne: 108 si (106 no) Caratteristiche materne + MAP + PI u.: 192 si (22 no) “ + MAP + PI u. + PAPP-A: 198 si (16 no) “ + MAP + PI u. + PAPP-A + PLGF: 206 si (8 no) 16 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Review. LC Poon, KH Nicolaides. Prenatal Diagnosis 2014, 34, 618–627 17 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Review. LC Poon, KH Nicolaides. Prenatal Diagnosis 2014, 34, 618–627 18 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Dalla clinica alla statistica… It has been demonstrated that maternal demographic characteristics, including medical and obstetric history, are potentially useful in screening for PE only when the various factors are incorporated into a combined algorithm derived by multivariate analysis. Certain variables, including advancing maternal age over 35 years, increasing weight, Afro-Caribbean and South Asian racial origin, previous pregnancy with PE, conception by in vitro fertilization (IVF) and a medical history of chronic hypertension, preexisting diabetes mellitus, and systemic lupus erythematosus or antiphospholipid syndrome, increase the risk for development of PE. Estimated detection rate of PE requiring delivery before 34 weeks’ gestation in screening by maternal factors is 51% at false-positive rate of 10%. LC Poon, K H Nicolaides. Early Prediction of Preeclampsia. Obstetrics and Gynecology International. Volume 2014, Article ID 297397http://dx.doi.org/10.1155/2014/297397 19 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Dalla biochimica alla statistica… In biochemical testing, it is necessary to make adjustments in the measured maternal serum metabolite concentration to correct for certain maternal and pregnancy characteristics as well as the machine and reagents used for the assays, and the serum metabolite concentration is then expressed in a multiple of the expected median (MoM) of the normal. First-trimester maternal serum concentrations of PAPP-A and PlGF have shown to be affected by gestational age at screening, maternal weight, racial origin, cigarette smoking, conception by IVF, nulliparity and pre-existing diabetes mellitus. In addition, serum PlGF is also affected by maternal age. Consequently, the measured concentrations of PAPP-A and PlGF must be adjusted for these variables before comparing results with pathological pregnancies. The MoM values of PAPP-A and PlGF are significantly reduced at 11–13 weeks’ gestation in women who subsequently develop PE. LC Poon, K H Nicolaides. Early Prediction of Preeclampsia. Obstetrics and Gynecology International. Volume 2014, Article ID 297397http://dx.doi.org/10.1155/2014/297397 20 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Conclusioni: • Using multivariate analysis in a large study population, we have identified the independent predictive value of each obstetric, demographic and maternal serum marker. • Mathematical modelling suggests high predictive ability at a reasonable falsepositive rate; prospective studies are underway to confirm the predictive values. ( ? ? ? ? ) LC Poon, K H Nicolaides. Early Prediction of Preeclampsia. Obstetrics and Gynecology International. Volume 2014, Article ID 297397http://dx.doi.org/10.1155/2014/297397 21 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 King’s College Vs ??? Resto del Mondo 22 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 The aim of this study is to validate the Fetal Medicine Foundation (FMF) multiple logistic regression algorithm for prediction of risk of pre-eclampsia in an Australian population. This model, which predicts risk using the population rate of pre-eclampsia, a variety of demographic factors, mean maternal arterial blood pressure (MAP), uterine artery PI (UtA PI) and pregnancy-associated plasma protein A (PAPP-A), has been shown to predict early-onset preeclampsia (delivery < 34 weeks) in 95% of women at a 10% FPR. Conclusions: This study shows that the FMF early pre-eclampsia algorithm is effective in an Australian population FJ Park et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology 2013; 53: 532–539 23 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Objective. To investigate the performance of a multivariable model combining a priori clinical characteristics and biomarkers to detect, early in pregnancy, women at higher risk of developing pre-eclampsia (PE). Methods. We selected a priori clinical characteristics and promising markers to create multivariable logistic regression models: body mass index (BMI), mean arterial pressure (MAP), placental growth factor (PlGF), soluble Fms-like tyrosine kinase-1 (sFlt-1), pregnancy-associated plasma protein A (PAPP-A) and inhibin A. Results. At false-positive rates of 10%, the estimated detection rates were between 39% (19–59%) and 50% (34–66%). Conclusions. In a population with a low prevalence of preterm PE (0.2%), a multivariable risk algorithm using an a priori combination of clinical characteristics and biochemical markers did not reach a performance justifying clinical implementation as screening test early in pregnancy. Y Giguère, et al. Screening for pre-eclampsia early in pregnancy. BJOG 2014; DOI: 10.1111/1471-0528.13050. Settembre 2014 (Canada) 24 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Objective: To develop a predictive model for preeclampsia using clinical, biochemical (PlGF) and ultrasound markers (UtA PI) during the first trimester of pregnancy. Results: Different combined models were generated by logistic regression analysis, and the detection rate (with a fixed 10% false-positive rate) was 47% and 29% for early- and late-onset pre-eclampsia, respectively. Conclusion: Regression models which include maternal characteristics, UtA Doppler and PlGF can apparently predict approximately half of pregnancies that will be complicated by early-onset pre-eclampsia. We believe more research in several areas is needed to aid in the creation of a better and more population-specific screening test for pre-eclampsia during the first trimester of pregnancy. M. Parra-Cordero et al. Prediction of early and late pre-eclampsia from… Ultrasound Obstet Gynecol 2013; 41: 538–544 (Cile) 25 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Am J Obstet Gynecol 2013;208:203.e1-10 26 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Nota >>> FMF: Caratteristiche materne + MAP + PI u.: 89.7% (FPR 10%) Am J Obstet Gynecol 2013;208:203.e1-10 27 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 28 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 CONCLUSION: A multivariable analysis of clinical data and biochemical markers in the first trimester did not identify a model that had clinical utility for predicting preeclampsia in a nulliparous population at low risk. 29 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Objective: To evaluate the performance of published first-trimester prediction algorithms for pre-eclampsia (PE) in a prospectively enrolled cohort of women. Results: Six early and two late PE prediction algorithms were applicable to 871–2962 women, depending on the variables required. The prevalence of early PE was 1.0–1.2% and of late PE was 4.1–5.0% in these patient subsets. One early PE prediction algorithm performed better than in the original publication (80% detection rate (DR) of early PE for 10% false-positive rate (FPR)); the remaining five prediction algorithms underperformed (29–53% DR). Conclusion: First-trimester prediction algorithms for PE share a high negative predictive value if applied to an external population but underperform in their ability to correctly identify women who develop PE. Further research is required to determine the factors responsible for the suboptimal external validity N. Oliveira et al. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol 2014; 44: 279–285 (Baltimora, USA) 30 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Objective: To evaluate the performance of published first-trimester prediction algorithms for pre-eclampsia (PE) in a prospectively enrolled cohort of women. Results: Six early and two late PE prediction algorithms were applicable to 871–2962 women, depending on the variables required. The prevalence of early PE was 1.0–1.2% and of late PE was 4.1–5.0% in these patient subsets. One early PE prediction algorithm performed better than in the original publication (80% detection rate (DR) of early PE for 10% false-positive rate (FPR)); the remaining five prediction algorithms underperformed (29–53% DR). Conclusion: First-trimester prediction algorithms for PE share a high negative predictive value if applied to an external population but underperform in their ability to correctly identify women who develop PE. Further research is required to determine the factors responsible for the suboptimal external validity N. Oliveira et al. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol 2014; 44: 279–285 (Baltimora, USA) 31 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 ML LeFevre, U.S.P.S.T.F. Clinical Guideline. Low-Dose Aspirin to Prevent Morbidity and Mortality From Preeclampsia. Annals of Internal Medicine. On line: www.annals.org. Sett 2014 Recommendation: The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation) Commento della LG: Evidence did not demonstrate benefit of starting aspirin earlier (12 to 16 weeks) rather than later (>16 weeks) in pregnancy Population: This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin. 32 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Risk Assessment. A chi? A) Pregnant women are at high risk for preeclampsia if they have 1 or more of the following risk factors: • History of preeclampsia, especially when accompanied by an adverse outcome • Multifetal gestation • Chronic hypertension • Type 1 or 2 diabetes • Renal disease • Autoimmune disease (i.e., systemic lupus erythematosus, the antiphospholipid syndrome Recommend low-dose aspirin if the patient has >1 of these high-risk factors. 33 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Risk Assessment. A chi? B) Pregnant women are at … moderate-risk … for preeclampsia: • Nulliparity • Obesity (body mass index >30 kg/m2) • Family history of preeclampsia (mother or sister) • Sociodemographic characteristics (African American race, low socioeconomic status) • Age >35 y • Personal history factors (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, >10-y pregnancy interval) Consider low-dose aspirin if the patient has several of these moderate-risk factors 34 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Assessment of Risk for Preeclampsia There are no validated methods of identifying women at high risk for preeclampsia on the basis of biomarkers, clinical diagnostic tests, or medical history 35 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 L’utilizzo dei diversi sistemi matematici di «screening» precoce della preeclampsia è sconsigliato/ignorato da: • NICE • WHO • ACOG • USPSTF • American Heart Association • American Stroke Association • American Academy of Family Physicians FMF (UK) ritiene necessari ulteriori studi per validare lo screening… 36 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 King’s College 2 Resto del Mondo 6 37 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 A prospective cohort of 9,462 pregnancies undergoing first-trimester screening. Logistic regression predictive models were developed for early and late PE (cut-off 34 weeks’ gestation at delivery). Data included the a priori risk (maternal characteristics), mean arterial pressure (MAP) and uterine artery (UtA) Doppler (11-13 weeks) in all cases. Plasma levels (8-11 weeks) of hCG, PAPP-A, placental growth factor (PlGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1) was analyzed Results: The best model for early PE (n=57, 0.6%) included a priori risk, MAP, UtA Doppler, PlGF and sFlt-1 achieving detection rates (DR) of 87.7% and 91.2% for 5% and 10% false-positive rates (FPR), respectively. For late PE (n=246, 2.6%), the best model included the a priori risk, MAP, UtA Doppler, PlGF and sFlt-1 achieving DR of 68.3% and 76.4% at 5% and 10% of FPR, respectively. Crovetto F et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters and angiogenic factors. Prenat Diagn. 2014 Oct 24. in press 38 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Uno sguardo alla biochimica: • PAPP-A MoM and fß-HCG MoM had no statistically significance for both PE groups. • PlGF was significantly lower in early PE (p<0.001) compared to unaffected group and to late PE (p<0.001), and in late PE compared to unaffected cases (p<0.001); • sFlt-1 was significantly higher in early PE (p<0.001) and in late PE (p<0.001) compared to unaffected cases; • sFlt-1/PlGF ratio was significantly higher in both PE groups compared to unaffected (early PE p<0.001, late PE p<0.001), and it was also greater in early PE compared to late-onset cases (p<0.001). Crovetto F et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters and angiogenic factors. Prenat Diagn. 2014 Oct 24. in press 39 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 meno 5 slides… 40 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio) … neither the maternal factors nor the serum biomarkers, either alone or combined, had an adequate detection rate for either all HDP, or GH, or PE developing at ≥37 weeks of gestation Using data from the Maternal Fetal Medicine Foundation (MFMF), the use of combined maternal factors, biophysical and biochemical markers increases the Detection Rate to 95% for PE requiring delivery at <34 weeks of gestation with an FPR of 10%. However, the positive predictive value (PPV) for such a screen remained <10%. The study by Giguère/Forest, … women at very low risk … They found that a clinical model that included maternal risk factors, BMI and MAP had a detection rate of 54% and a PPV of 3% at an FPR of 10% for PE <34 weeks of gestation. 41 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio) … given the poor PPV for PE at <34 weeks, and the poor detection rates for all cases of GH/PE the clinical implications of a PE screen test in the first trimester remain unclear. … some authors and commercial screening companies have been promoting a combination of maternal factors, MAP, uterine artery Doppler and serum biomarkers obtained in the first trimester as a screening test to identify those at high risk for developing early-onset PE (95% detection rate with FPR of 10%). They recommended that women who screen positive will benefit from receiving low-dose aspirin (LDA) for prevention of early onset PE, as well as from receiving intensive antenatal monitoring and early intervention. 42 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio) However, whether the information provided with this screen will affect patient outcome or is cost-effective remains unknown. At present, there is no clinical trial that demonstrates a benefit from using LDA in such a population A major concern of first-trimester screening for PE without evidence of benefit is the unintended consequences (conseguenze involontarie!!!) of those identified as false-positives (97%) of cases for a PPV of 3%. 43 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Sibai BM. First-trimester screening with combined maternal clinical factors, biophysical and biomarkers to predict preterm pre-eclampsia and hypertensive disorders: are they ready for clinical use? BJOG 2014; DOI: 10.1111/1471-0528.13052 (Luglio) Some authors and commercial entities have recommended that those who screen positive should have: • more frequent visits, • more maternal and fetal testing, • bed rest and other • interventions that could be potentially harmful to both mother and infant. Currently, there are no prospective studies or randomised trials evaluating the benefits and risks of first trimester screening for prediction of PE. Until then, the use of such tests for screening should remain experimental 44 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Test biochimici e preeclampsia - Conclusioni • It is understandable that a single biomarker cannot be used as an accurate predictive tool for diagnosing a complex disorder like PE. • Therefore, analysis of a set of biomarkers is imperative for early detection of PE. • However, the cost of the test, its acceptability at large and its quality control, are of paramount importance. • It is hoped that extensive research being done in this arena will ultimately give rise to affordable diagnostic tools that will allow timely interventions of this complex disease process Manisha Kar. Role of Biomarkers in Early Detection of Preeclampsia. Journal of Clinical and Diagnostic Research. 2014 Apr, Vol-8(4): BE01-BE04 45 Test biochimici: prevedere la preeclampsia Bergamo, 20 Novembre 2014 Grazie... 46